News & Updates

Show Multimedia Only

Social deprivation tied to higher glaucoma risk

16 Oct 2023

Personal poverty, as defined by not driving a personal vehicle to the appointment, and neighbourhood-level poverty appear to contribute to higher rates of screening positive for glaucoma or suspected glaucoma, suggests a study.

16 Oct 2023

Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients

16 Oct 2023 by

In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.

16 Oct 2023

Physical activity boosts functional performance in MM

16 Oct 2023 by

Exercises that include walking and resistance training are effective interventions that improve frailty in patients with multiple myeloma (MM) who are receiving systemic treatment, according to a new study.

16 Oct 2023

$Real-world experience of treating relapsed or refractory diffuse large B-cell lymphoma with tisagenlecleucel in Hong Kong$

Real-world experience of treating relapsed or refractory diffuse large B-cell lymphoma with tisagenlecleucel in Hong Kong

16 Oct 2023

Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have poor outcomes with traditional therapies. However, phase 3 clinical trials of tisagenlecleucel, a CD-19 directed chimeric antigen receptor T-cell (CAR-T) therapy, have shown improved ORR, CR, PFS and OS in patients with r/r DLBCL, giving hope to these patients. Long-term real-world data from Hong Kong has also shown improved outcomes with tisagenlecleucel in these patients.

16 Oct 2023

HIV treatment discontinuation less frequent with B/F/TAF than DTG/3TC

16 Oct 2023 by

In a real-world cohort, virologically suppressed HIV patients who switched from a prior regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were less likely to discontinue their regimen than those who switched to dolutegravir/lamivudine (DTG/3TC).

16 Oct 2023

RSV vaccine effective across two seasons

16 Oct 2023 by

The respiratory syncytial virus (RSV) vaccine by GSK demonstrated sustained effectiveness of about 67 percent among adults 60 years or older across two full RSV seasons in a phase III study, says an infectious disease expert who reported findings at IDWeek 2023.

16 Oct 2023